Cabaletta Bio CABA 深 沪
等待开盘 11-01 09:30:00 美东时间
3.61
+1.140
+46.15%
华盛通- 最 高3.67
- 今 开2.61
- 成交量 3575.50万股
- 最 低 2.56
- 昨 收 2.47
- 总市值 3.30亿
- 52周最高 5.46
- 市盈率 静 --
- 换手率 0.04%
- 52周最低 0.9857
- 委 比 73.23%
- 总股本 9146.52万
- 历史最高 26.35
- 量 比 13.84
- 振 幅 44.94%
- 历史最低 0.59
- 每 手 1
- 风险率 0.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Cabaletta Bio (NASDAQ:CABA) shares rose 36.6% to $3.38 during Friday's...
今天 01:06
Cabaletta Bio Announces Clinical Data And Development Updates Across RESET-Myositis, RESET-SSc And RESET-SLE Trials Evaluating Rese-Cel
– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no
10-27 19:10
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
Cabaletta Bio announced positive clinical data for rese-cel in treating patients with myositis, systemic sclerosis (SSc), and lupus. In the Phase 1/2 DM/ASyS cohort, all patients meeting inclusion criteria achieved major clinical responses without immunomodulators. A registrational trial for DM/ASyS is planned with 14 patients and a 16-week endpoint. In SSc, all patients with sufficient follow-up showed transformative responses off immunomodulato...
10-27 11:00
High Tide Celebrates Four Years of the Cabana Club
The Company Raises Its Long-Term Targets to 3 Million Cabana Club Members and 350 Canna Cabana Locations Across Canada Canna Cabana Named Canada's Most Recognizable Cannabis Retailer CALGARY...
10-21 20:00
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
Cabaletta Bio appoints Steve Gavel as Chief Commercial Officer, who brings extensive CAR T experience from Legend Biotech. Gavel will lead global commercial strategy for rese-cel, with a BLA submission expected in 2027. He previously led the successful launch of CARVYKTI® at Legend Biotech and has a strong track record in commercializing cell therapies. The company anticipates Gavel's leadership will enhance the commercialization efforts for rese...
10-14 12:00
Analysts’ Top Healthcare Picks: Cabaletta Bio (CABA), Icon (ICLR)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
10-14 01:50
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
10-13 11:26
Cabaletta Bio Presents Promising RESET-PV Trial Data
Cabaletta Bio ( ($CABA) ) has shared an announcement. On October 9, 2025, Cabal...
10-10 00:28
Cabaletta Bio Reports Initial Results For Rese-cel In Pemphigus Vulgaris Without Preconditioning; Shows Complete B Cell Depletion, Rapid Reduction In Autoantibodies And Near-complete Resolution Of Clinical Symptoms In Two Of Three Refractory Patients
– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators since infusion and
10-10 00:11
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
<p align="justify">Cabaletta Bio has presented initial dose data from the RESET-PV trial evaluating rese-cel without preconditioning in three patients with pemphigus vulgaris. Results showed complete B cell depletion, rapid reduction in autoantibodies, and significant clinical symptom improvement in two of the three patients. Rese-cel was well-tolerated with no severe adverse events. These findings suggest potential for simplifying treatment regi...
10-09 16:00
